Page last updated: 2024-12-06

androstane-3,17-diol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Androstane-3,17-diol: The unspecified form of the steroid, normally a major metabolite of TESTOSTERONE with androgenic activity. It has been implicated as a regulator of gonadotropin secretion. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID32801
CHEBI ID27727
SCHEMBL ID3366554
MeSH IDM0023245

Synonyms (11)

Synonym
CHEBI:27727
25126-76-5
androstane-3,17-diol
SCHEMBL3366554
CBMYJHIOYJEBSB-CAHXEBCQSA-N
5.xi.-androstane-3.xi.,17.xi.-diol
5.xi.-androstane-3,17-diol
DTXSID00859494
Q27103288
5beta-androstan-3alpha,17alpha-diol
(3as,3br,9as,9bs,11as)-9a,11a-dimethyl-hexadecahydro-1h-cyclopenta[a]phenanthrene-1,7-diol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Apart from daily stress of paralysis preceding intubation no irreversible toxic changes were detected by laboratory and morphological tests."( Summary of safety tests with pipecurium bromide, a new neuromuscular blocking agent.
Cholnoky, E, 1980
)
0.26

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic variables were similar for the two groups, and pharmacodynamic analysis revealed a similar sensitivity at the neuromuscular junction."( Pharmacokinetics and pharmacodynamics of pipecuronium bromide (Arduan) in elderly surgical patients.
Diaz, J; Jamdar, SC; Matteo, RS; Ornstein, E; Schwartz, AE, 1992
)
0.28
" The elimination half-life in animals was found to be around 40 min, in humans between 44-137 min."( [Pharmacokinetics and metabolism of pipecuronium bromide (Arduan)].
Vereczkey, L, 1992
)
0.28
"To study the effects of succinylcholine on subsequent pharmacodynamics of nondepolarizing muscle relaxants, a comparative pharmacodynamic study was carried out in patients having balanced anesthesia (thiopental, fentanyl, nitrous oxide/oxygen) in whom equipotent doses of pipecuronium (80 micrograms/kg) and pancuronium (100 micrograms/kg) were given with or without prior administration of succinylcholine (1 mg/kg)."( Effects of succinylcholine on the pharmacodynamics of pipecuronium and pancuronium.
Dubois, MY; Fleming, NW; Lea, DE, 1991
)
0.28
" The pharmacokinetic parameters of pipecuronium were compared with those of pancuronium (0."( [Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man].
Hanaoka, K; Kushida, Y; Murakami, S; Numata, K; Sugai, N; Yajima, C; Yamamoto, K; Yamamura, H, 1990
)
0.28
" In connection with the pharmacodynamic evaluation, literature on the pipecuronium bromide and on the administration of the muscle relaxants in paediatric anaesthesiology is summarized."( [A pharmacodynamic study of pipecuronium bromide (Arduan) in newborn infants, infants and children].
Praefort, L, 1990
)
0.28
" The pharmacokinetic parameters derived by compartmental modelling were (normal vs."( The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide.
Caldwell, JE; Canfell, PC; Castagnoli, KP; Fahey, MR; Fisher, DM; Lynam, DP; Miller, RD, 1989
)
0.28
" Except for the volume of central compartment, all other pharmacokinetic variables differed significantly between the two experimental groups."( Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles.
Agoston, S; Caldwell, JE; Chung, K; Khuenl-Brady, KS; Miller, RD; Sharma, M, 1989
)
0.28
" Absence of renal function significantly altered the pharmacokinetic parameters and prolonged the time-course of the neuromuscular blocking effects of pipecuronium."( Pharmacokinetics and disposition of pipecuronium bromide in the cat.
Agoston, S; Houwertjes, MC; Kersten, UW; Vandenbrom, RH; Wierda, JM, 1988
)
0.27
" The pharmacokinetic parameters of pipecurium bromide were found as follows: apparent distribution volume V beta = 261 +/- 28 (n = 8) ml/kg, plasma clearance Cl = 320 +/- 55 (n = 8) ml/min."( Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans.
Szabó, G; Tassonyi, E; Vereczkey, L, 1981
)
0.26
"Twenty-five men, 60-80 yr old, participated in a pharmacokinetic study to compare three doses (16, 32, and 64 mg/day, n = 8 or 9 in each group) of 5alpha-dihydrotestosterone (DHT) gel (0."( Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study.
Berman, N; Dudley, RE; Faulkner, SM; Iranmanesh, A; McDonald, V; Steiner, B; Swerdloff, RS; Veldhuis, JD; Wang, C; Ziel, F, 1998
)
0.3
"A prospective, randomized, double-blind, placebo-controlled pharmacokinetic study."( Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men.
Acacio, BD; Jafarian, N; Mullin, P; Saadat, P; Sokol, RZ; Stanczyk, FZ, 2004
)
0.32
" No significant changes were observed in pharmacokinetic values."( Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men.
Acacio, BD; Jafarian, N; Mullin, P; Saadat, P; Sokol, RZ; Stanczyk, FZ, 2004
)
0.32
" Baseline-corrected and uncorrected serum TT and fT pharmacokinetic parameters (AUC0-24, C avg, Cmax, and Tmax) were calculated using a standard model-independent approach."( Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women.
Bell, RJ; Davis, SR; Fooladi, E; Reuter, SE; Robinson, PJ, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
"The metabolic effects of cyproterone acetate (2 mg) combined with a new dose level of ethinyl estradiol (35 micrograms) were studied over a one-year period in 31 patients presenting moderate clinical hyperandrogenism."( Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 micrograms) in 31 patients.
Cathelineau, G; Fiet, J; Hardy, N; Martineau, I; Vexiau, P; Vexiau-Robert, D; Villette, JM, 1990
)
0.28
" The effects of different doses of testosterone and its 5 alpha-reduced metabolites as well as the effect of testosterone in combination with oestradiol on gonadotrophin secretion were evaluated."( Control of gonadotrophin secretion by steroid hormones in castrated male transsexuals. II. Effects of androgens alone and in combination with oestradiol on the secretions of FSH and LH.
Goh, HH; Karim, SM; Ratnam, SS, 1981
)
0.26

Bioavailability

ExcerptReferenceRelevance
" Synthetic neurosteroids that exhibit better bioavailability and efficacy and drugs that enhance neurosteroid synthesis have therapeutic potential in anxiety, epilepsy, and other brain disorders."( Neurosteroids: endogenous role in the human brain and therapeutic potentials.
Reddy, DS, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" The prostate glands, on the other hand, showed better maintenance in the higher dosage group."( The effects of 5alpha-reduced androgens on maintenance and regeneration of prostate glands and seminal vesicles in castrated and hypophysectomized rats.
Ahmad, N; Haltmeyer, GC; Warren, DW, 1978
)
0.26
" The dose-response and time course of response for the three steriods were nearly identical."( Serum 5alpha-androstane-3alpha,17beta-diol, androsterone, and testosterone concentrations in the male rat. Influence of age and gonadotropin stimulation.
Moger, WH, 1977
)
0.26
" Dosage of DHT was varied from 500 mcg to 1 mg and time of injection was varied from concurrent with EB injection to 12 hours after."( Estrogen-induced sexual receptivity and localization of 3H-estradiol in brains of female mice: effects of 5 alpha-reduced androgens, progestins and cyproterone acetate.
Gray, HE; Jasper, TW; Luttge, WG; Sheets, CS, 1977
)
0.26
" The cumulative dose-response to pipecuronium was determined in both patients during nitrous oxide-oxygen-narcotic anaesthesia."( Myasthenia gravis and pipecuronium--report of two cases.
Ashour, M; Messahel, F; Naguib, M; Sari-Kouzel, A; Seraj, M, 1992
)
0.28
" Responses were defined in terms of percent depression in first-twitch height and train-of-four response, and the dose-response curves were constructed after probit transformation of the responses."( Pipecuronium-induced neuromuscular blockade during nitrous oxide-fentanyl, enflurane, isoflurane, and halothane anesthesia in surgical patients.
Abdulrazik, E; Naguib, M; Seraj, M, 1992
)
0.28
" In order to obtain a stable dosage form liophylized ampoules containing mannitol were prepared."( [Pharmaceutic development of injectable Arduan].
Deákné, RE; Guti, Z; Rádi, E, 1992
)
0.28
" Before its introduction into clinical practice in the USA, in the first phase of this study the neuromuscular potency of pipecuronium was determined under "balanced" and enflurance anaesthesia by the cumulative log dose-response method in 30 patients each."( Neuromuscular and cardiovascular effects of pipecuronium.
Duncalf, D; Foldes, FF; Goldiner, PL; Nagashima, H; Nguyen, HD, 1990
)
0.28
"The purpose of the study was to measure the neuromuscular effects of pipecuronium bromide (Arduan) and to determine its dosage in paediatric anaesthesiology by recording dose-effect curves in children, infants and newborn babies during diazepam, ketamine, fentanyl, nitrous oxide anaesthesia."( [A pharmacodynamic study of pipecuronium bromide (Arduan) in newborn infants, infants and children].
Praefort, L, 1990
)
0.28
"We determined the cumulative dose-response relations of pipecuronium in infants and children during nitrous oxidehalothane anesthesia."( Clinical pharmacology of pipecuronium in infants and children during halothane anesthesia.
Brandom, BW; Cook, DR; Dong, ML; Pickle, D; Sarner, JB; Weinberger, MJ, 1990
)
0.28
"The dose-response of pipecuronium bromide, the time course of its neuromuscular blocking effects, and the reversibility of the residual block by neostigmine and edrophonium have been investigated in patients undergoing various types of anesthesia."( Dose-response relation and time course of action of pipecuronium bromide in humans anesthetized with nitrous oxide and isoflurane, halothane, or droperidol and fentanyl.
Agoston, S; Richardson, FJ; Wierda, JM, 1989
)
0.28
" We examined the dose-response relation of pipecuronium in 27 patients, ages 66-79 years, utilizing the incremental dose method under balanced anesthesia."( A dose-response evaluation of pipecuronium bromide in elderly patients under balanced anesthesia.
Azad, SS; Beach, CA; Goldberg, ME; Larijani, GE; Marr, AT; Seltzer, JL, 1989
)
0.28
"Cumulative dose-response curves were constructed to determine the comparative potency of pipecuronium and pancuronium."( Comparative potency of pipecuronium bromide and pancuronium bromide.
Mirakhur, RK; Stanley, JC, 1989
)
0.28
" We conclude that there is no clinical indication that the dosage of atracurium and vecuronium during inhalation anesthesia should be reduced, but the doses of pipecuronium and pancuronium should be reduced when prolonged paralysis is not desired."( Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.
Agoston, S; Hermans, J; Ket, JM; Koot, HW; Rashkovsky, OM; Swen, J, 1989
)
0.28
" It was found that LH was suppressed to intact levels by testosterone or its active metabolites at doses within the "physiologic dosage range" (equivalent in biological activity to endogenously secreted androgens)."( Pituitary-gonadal axis before puberty: evaluation of testicular steroids in the male rat.
Eldrige, JC; Mahesh, VB, 1974
)
0.25
" In contradistinction to other low dosage combination oral contraceptives this new oral contraceptive has a good control of the menstrual cycle."( [Clinical and biochemical results during the treatment with marvelon, a new oral contraceptive (author's transl)].
Huber, P; Mall-Haefeli, M; Weijers, MJ; Werner-Zodrow, I, 1982
)
0.26
" Dosage was limited by prolonged paralysis time requiring artificial ventilation."( Summary of safety tests with pipecurium bromide, a new neuromuscular blocking agent.
Cholnoky, E, 1980
)
0.26
"8 mg dosage when compared with castrated controls."( Effect of hormone injections on levels of cytosolic receptors for estrogen, androgen and progesterone in dog prostate.
Dube, JY; Frenette, G; Tremblay, RR, 1982
)
0.26
" Serum 3 alpha-Diol content in the adult rats was either unaltered or increased significantly depending on the LHRH dosage employed during sexual development."( Delay in the age of balano-preputial skinfold cleavage and alterations in serum profiles of testosterone, 5 alpha-androstane-3 alpha,17 beta-diol, and gonadotropins in adult rats treated during puberty with luteinizing hormone releasing hormone.
Stalvey, JR; Warren, DW; Wisner, JR, 1983
)
0.27
" Neither the highest dosage of 5 mg/day for three days, nor 2 mg/day for 15 days could induce lordosis behavior in females that displayed typically high lordosis quotients with low dosages of estradiol (E)."( 5 alpha-androstane-3 beta, 17 beta-diol binds to androgen and estrogen receptors without activating copulatory behavior in female rats.
Doering, CH; Gladue, BA, 1982
)
0.26
" Further, there is a dose-response relationship but no apparent synergism between exogenous dihydrotestosterone and incubation temperature."( Temperature and non-aromatizable androgens: a common pathway in male sex determination in a turtle with temperature-dependent sex determination?
Bergeron, JM; Cantú, AR; Crews, D, 1996
)
0.29
" 1, P and 3 alpha-Diol both produced analgesia and had biphasic dose-response effects when administered singly."( Analgesic effects of the neurosteroid 3 alpha-androstanediol.
Erskine, MS; Frye, CA; Rao, PN; Van Keuren, KR, 1996
)
0.29
" The highest dosage of 3 alpha-Diol (7."( Behavioral effects of 3 alpha-androstanediol. I: Modulation of sexual receptivity and promotion of GABA-stimulated chloride flux.
Erskine, MS; Frye, CA; Van Keuren, KR, 1996
)
0.29
" Nine natural and synthetic androgens were tested for their effectiveness in inducing postnatal prostatic development using 808 newborn rat APs in 68 dose-response experiments."( Efficacy of various natural and synthetic androgens to induce ductal branching morphogenesis in the developing anterior rat prostate.
Cunha, GR; Foster, BA, 1999
)
0.3
" No dose-response relationships were observed."( Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study.
Feldman, HA; Kalish, LA; Longcope, C; McKinlay, JB; Mohr, BA, 2001
)
0.31
" In Experiment 4, a high dosage of 5alpha-dihydrotestosterone was more anxiolytic than a high dosage of estradiol benzoate, suggesting that testosterone action may require 5alpha-reduction."( Testosterone rapidly reduces anxiety in male house mice (Mus musculus).
Aikey, JL; Anmuth, DM; James, PJ; Nyby, JG, 2002
)
0.31
" Both diols induced hER-mediated reporter gene transactivation in a dose-response manner, similar to that induced by oestradiol, though with lower potency, an effect that was abolished by ICI-182 780."( Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern.
Borja-Cacho, E; Damián-Matsumura, P; García-Becerra, R; González, L; Larrea, F; Lemus, AE; Pérez-Palacios, G; Santillán, R, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
17-hydroxy steroidA hydroxy steroid carrying a hydroxy group at position 17.
3-hydroxy steroidAny hydroxy steroid carrying a hydroxy group at position 3.
androstanoidAny steroid based on an androstane skeleton and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Alternative pathway of fetal androgen synthesis717

Research

Studies (1,064)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990604 (56.77)18.7374
1990's224 (21.05)18.2507
2000's151 (14.19)29.6817
2010's81 (7.61)24.3611
2020's4 (0.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.08 (24.57)
Research Supply Index7.08 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials64 (5.69%)5.53%
Reviews42 (3.74%)6.00%
Case Studies11 (0.98%)4.05%
Observational0 (0.00%)0.25%
Other1,007 (89.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]